Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors

References

• Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines 2019;7:97.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information.
   Google Scholar
• Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 2021;17:696–701.
   PubMed Web of Science ®Google Scholar
• https://investors.biogen.com/static-files/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb.
   Google Scholar
• Geula C, Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer’s disease. Drugs Today (Barc) 2004;40:711–21.
   PubMed Web of Science ®Google Scholar
• Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer’s disease–interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005;30:895–908.
   PubMed Web of Science ®Google Scholar
• Abeysinghe A, Deshapriya R, Udawatte C. Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci 2020;256:117996.
   PubMed Web of Science ®Google Scholar
• Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer’s disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 2006;61:267–71.
   PubMed Web of Science ®Google Scholar
• Coulthard E, Singh-Curry V, Husain M. Treatment of attention deficits in neurological disorders. Curr Opin Neurol 2006;19:613–8.
   PubMed Web of Science ®Google Scholar
• Villarroya M, García AG, Marco-Contelles J, López MG. An update on the pharmacology of galantamine. Expert Opin Investig Drugs 2007;16:1987–98.
   PubMed Web of Science ®Google Scholar
• Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain 2006;129:2840–55.
   PubMed Web of Science ®Google Scholar
• Kamal MA, Qu X, Yu QS, et al. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm 2008;115:889–98.
   PubMed Web of Science ®Google Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006;9:101–24.
   PubMed Web of Science ®Google Scholar
• Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A 2006;103:8628–33.
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–8.
   PubMed Web of Science ®Google Scholar
• Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333–44.
   PubMed Web of Science ®Google Scholar
• Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322–5.
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. A beta oligomers – a decade of discovery. J Neurochem 2007;101:1172–84.
   PubMed Web of Science ®Google Scholar
• Leung D, Abbenante G, Fairlie DP. Protease inhibitors: current status and future prospects. J Med Chem 2000;43:305–41.
   PubMed Web of Science ®Google Scholar
• Durham TB, Shepherd TA. Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel 2006;9:776–91.
   PubMed Web of Science ®Google Scholar
• McDade E, Voytyuk I, Aisen P, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol 2021;17:703–14.
   PubMed Web of Science ®Google Scholar
• Hu X, Das B, Hou H, et al. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J Exp Med 2018;215:927–40.
   PubMed Web of Science ®Google Scholar
• Annicchiarico R, Federici A, Pettenati C, Caltagirone C. Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life. Ther Clin Risk Manag 2007;3:1113–23.
   PubMedGoogle Scholar
• Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007;4:277–93.
   PubMed Web of Science ®Google Scholar
• Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules 2020;25:5789.
   PubMed Web of Science ®Google Scholar
• Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 2011;18:4949–75.
   PubMed Web of Science ®Google Scholar
• Paez JA, Campillo NE. Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer’s disease and less well-known diseases. Curr Med Chem 2019;26:3300–40.
   PubMed Web of Science ®Google Scholar
• Rook Y, Schmidtke KU, Gaube F, et al. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem 2010;53:3611–7.
   PubMed Web of Science ®Google Scholar
• Incerti M, Flammini L, Saccani F, et al. Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity. ChemMedChem 2010;5:1143–9.
   PubMed Web of Science ®Google Scholar
• Piazzi L, Cavalli A, Colizzi F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 2008;18:423–6.
   PubMed Web of Science ®Google Scholar
• Pfannstiel K, Janecke J. Representation of o-hydrazino-benzoic acids and indazolones by reduction of diazotated anthranilic acids with sulphuric acid. Chem Ber 1942;75:1096–107.
   Google Scholar
• Baiocchi L, Corsi G, Palazzo G. Synthesis, properties and reactions of 1H-indazol-3-ols and 1-2-dihydro-3h-indazol-3-ones. Synthesis-Stuttgart 1978;1978:633–48.
   Google Scholar
• Arán VJ, Flores M, Munoz P, et al. Analogues of cytostatic, fused indazolinones: Synthesis, conformational analysis and cytostatic activity against HeLa cells of some 1-substituted indazolols, 2-substituted indazolinones, and related compounds. Liebigs Ann 2006;1996:683–91.
   Google Scholar
• Gonzalez-Naranjo P, Perez-Macias N, Campillo NE, et al. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer’s disease. Eur J Med Chem 2014;73:56–72.
   PubMed Web of Science ®Google Scholar
• GraphPad_Prism. 5.0; San Diego (CA): GraphPad Software; 2013.
   Google Scholar
• http://tools.invitrogen.com/content/sfs/manuals/L0724.pdf.
   Google Scholar
• Ou B, Hampsch-Woodill M, Prior RL. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem 2001;49:4619–26.
   PubMed Web of Science ®Google Scholar
• Davalos A, Gomez-Cordoves C, Bartolome B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J Agric Food Chem 2004;52:48–54.
   PubMed Web of Science ®Google Scholar
• Lauwiner MR, P, Wissmann R. Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of monosubstituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite. Appl Catal A-Gen 1998;172:7.
   Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. Jr. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Lee JY, Woo ER, Kang KW. Inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by acteoside through blocking of AP-1 activation. J Ethnopharmacol 2005;97:561–6.
   PubMed Web of Science ®Google Scholar
• Chan MM, Ho CT, Huang HI. Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Cancer Lett 1995;96:23–9.
   PubMed Web of Science ®Google Scholar
• Pike CJ, Burdick D, Walencewicz AJ, et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676–87.
   PubMed Web of Science ®Google Scholar
• Geula C, Wu CK, Saroff D, et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 1998;4:827–31.
   PubMed Web of Science ®Google Scholar
• Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751–7.
   PubMed Web of Science ®Google Scholar
• Kruger TM, Bell KJ, Lansakara TI, et al. A soft mechanical phenotype of SH-SY5Y neuroblastoma and primary human neurons is resilient to oligomeric Abeta(1-42) injury. ACS Chem Neurosci 2020;11:840–50.
   PubMed Web of Science ®Google Scholar
• Castillo WO, Aristizabal-Pachon AF, de Lima Montaldi AP, et al. Galanthamine decreases genotoxicity and cell death induced by beta-amyloid peptide in SH-SY5Y cell line. Neurotoxicology 2016;57:291–7.
   PubMed Web of Science ®Google Scholar